Glyco-Signatures in Colorectal Cancer: Multi-Omics Reveals New Biomarkers for Risk Stratification

WEBINAR

Abstract:

Colorectal cancer (CRC) remains the second-leading cause of cancer deaths globally, with approximately 1 million annual fatalities. Our innovative research applies integrated systems glycobiology to identify non-invasive prognostic markers crucial for improving patient outcomes.

Our comprehensive multi-omics approach—combining glycomics, glyco/proteomics, and transcriptomics—revealed that non-canonical paucimannosidic proteins create distinctive glyco-signatures in CRC tumors, originating from both tumor-infiltrating monocytes and cancer cells.

The study identified hexosaminidase subunit beta as a key truncating glyco-enzyme overexpressed in CRC tumors that facilitates paucimannosidic protein formation. Importantly, plasma hexosaminidase activity demonstrated significant correlation with five-year survival rates in a large CRC patient cohort.

This research showcases the untapped potential of multi-omics approaches to precisely map glycosylation changes during tumor development, unveiling promising new biomarkers for CRC risk stratification and potentially other cancers.

Takeaways:

• Discover the significance of non-invasive prognostic markers in colorectal cancer (CRC) and their potential to improve clinical decision-making and patient survival.
• Explore the integrated systems glycobiology approaches used in the study to identify new glyco-markers in CRC patient specimens through multi-omics data analysis.
• Understand the role of non-canonical paucimannosidic proteins and their origins from tumor-infiltrating monocytes and cancer cells in creating glyco-signatures associated with CRC.
• Learn how plasma hexosaminidase activity correlates with the five-year survival rates of CRC patients, highlighting the clinical implications of these findings."